Buy Benlysta (belimumab) Online
From $152.00
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that causes inflammation and tissue damage in multiple organs of the body and requires immunosuppressants and anti-inflammatory medications for treatment. Benlysta (belimumab) is a biologic medication that targets B-lymphocyte stimulator involved in the development of autoantibodies and inflammation in SLE, and is approved for adults and children aged 5 years and above with SLE and adults with active lupus nephritis. Clinical trials have shown that belimumab significantly reduces disease activity and symptoms in patients with SLE and improves renal response in patients with lupus nephritis. Nevertheless, belimumab can cause common side effects such as infections and musculoskeletal symptoms, and may increase the risk of depression and suicide ideation in patients with psychiatric illness.
Description
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that can cause tissue damage and chronic inflammation in multiple organs, including the skin, joints, kidneys, and heart. Treatment for SLE typically involves managing symptoms and preventing organ damage with immunosuppressive and anti-inflammatory medications.
Benlysta (belimumab) is a biologic medication that targets a specific molecule called B-lymphocyte stimulator (BLyS), which is involved in the development of autoantibodies and inflammatory responses in SLE. Belimumab is approved for use in conjunction with standard therapy for the treatment of adults and children aged 5 years and above with SLE, and for adults with active lupus nephritis (LN).
Clinical trials have shown that belimumab can reduce disease activity and improve symptoms in patients with SLE. In the BLISS-52 and BLISS-76 trials, which enrolled patients with active SLE despite standard therapy, belimumab significantly reduced disease activity and flares compared to placebo. Significant improvements were also seen in symptoms like fatigue, joint pain, and skin rash. In addition, a post-hoc analysis of the BLISS trials suggested that belimumab may be particularly effective in patients with autoantibodies that target the RNA protein, a common feature of severe SLE.
In a Phase III trial of belimumab in patients with active LN, the medication achieved the primary endpoint of renal response at week 104 in significantly more patients in the belimumab group compared to the placebo group. The medication was generally well-tolerated, with a similar safety profile to that observed in previous trials in patients with SLE.
The most common side effects of belimumab are infusion reactions, infections, and musculoskeletal symptoms. In addition, belimumab may increase the risk of depression and suicide ideation, and should be used with caution in patients with a history of psychiatric illness.
In summary, Benlysta (belimumab) is a biologic medication that can be used in combination with other medications to treat SLE and active LN in adults and children aged 5 years and above. The medication targets B-lymphocyte stimulator, a molecule involved in the development of autoantibodies and inflammatory responses in SLE. Clinical trials have shown that belimumab can reduce disease activity and improve symptoms in patients with SLE, and can also improve renal response in patients with active LN. However, belimumab may increase the risk of depression and suicide ideation and must be used with caution in patients with a history of psychiatric illness.
Additional information
| Package | Single-dose vial 120mg/5mL, Autoinjector pen 200 mg, 4x Autoinjector pen 200 mg, 12x Autoinjector pen 200 mg, Single-dose vial 400mg/20mL |
|---|
Reviews
There are no reviews yet.